What If Some Pediatric Mental Health Symptoms Are Driven by Inflammation?

The prevalence of depression and anxiety in children and adolescents has nearly doubled since the COVID-19 pandemic. Global rates are astounding:
- 25.2% for depression
- 20.5% for anxiety

The skyrocketing number of pediatric psychiatric cases suggests traditional treatment approaches are inadequate, such as:
- psychotherapies
- psychotropic medications

These approaches offer:
- poor adherence
- tolerability issues
- treatment resistance
- low efficacy (response rates below 50-70%)

Youth are especially vulnerable to side effects such as:
- suicidal ideation
- severe withdrawal symptoms

\ A Role For Inflammation?
Emerging evidence suggests that neuroinflammation, driven by elevated proinflammatory cytokines (e.g., IL-6, TNF-α), is a key factor in treatment-resistant cases. We argue that this is especially true in cases of sudden-onset, post-infectious triggers (e.g., PANS, Long COVID) or immune dysregulation. Further research is needed to develop protocols and guide clinical adoption.

Please share this so we can amplify this message.

Read our publication